Loading...

Company Overview: Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA)

2,008 views

Loading...

Loading...

Transcript

The interactive transcript could not be loaded.

Loading...

Rating is available when the video has been rented.
This feature is not available right now. Please try again later.
Published on Jan 19, 2017

http://dicerna.com/ SCN's Jane King interviews Douglas M. Fambrough, Ph.D., President & CEO of Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA). They discuss the biopharmaceutical company and its exciting proprietary drug platform GalXC™
Dicerna is an RNA interference-based biopharmaceutical company focused on the discovery and development of innovative treatments for rare, inherited diseases involving the liver and for other therapeutic areas in which the liver plays a key role including cardiovascular disease, chronic liver diseases, and liver infectious diseases.
• Their proprietary RNAi technology uses the body’s natural biological pathways to silence or “turn off” genes with a high degree of selectivity and specificity.

Loading...

When autoplay is enabled, a suggested video will automatically play next.

Up next


to add this to Watch Later

Add to

Loading playlists...